- The US Food and Drug Administration (USFDA) has approved Apretude-the world’s first-ever injectable medication capable of reducing the risk of acquiring HIV or HIV pre-exposure prophylaxis (PrEP).
- The injectable, known as Apretude or by its generic name, ‘cabotegravir extended-release injectable suspension,’ has been hailed as a gamechanger in the fight against HIV and comes as an alternative to daily pills currently used in HIV prevention like Truvada and Descovy.
- Apretude is given first as two initiation injections administered one month apart, and then every two months thereafter.
- Apretude has not been approved for HIV prevention anywhere outside the US, but regulators in several African countries are considering its approval.
GS TIMES UPSC PRELIMS 2022 CURRENT AFFAIRS BASED BASICS DAILY ONLINE TEST CLICK HERE
CLICK HERE DAILY CURRENT AFFAIRS QUIZ FOR STATE CIVIL SERVICES
